Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 12, 2021 07:30 ET | Source: Minerva Neurosciences, Inc

Minerva Neurosciences Reports First Quarter 2021 Financial Results and Business Updates

Top-line results from the open-label extension of phase 3 monotherapy trial of roluperidone for the treatment of negative symptoms of schizophrenia show continuous improvement in negative symptoms,...
May 11, 2021 16:15 ET | Source: Minerva Neurosciences, Inc

Minerva Neurosciences Announces the Results of the Phase 3 Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia Following the Completion of the 40-Week Open-Label Extension

Key results Continuous improvement in negative symptoms as measured by Positive and Negative Syndrome Scale (PANSS) Marder Negative Symptom Factor Score (NSFS) observed over one year (12-week...
May 05, 2021 17:10 ET | Source: Minerva Neurosciences, Inc

Minerva Neurosciences to Report First Quarter 2021 Financial Results and Business Updates on May 12, 2021

WALTHAM, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
March 08, 2021 07:30 ET | Source: Minerva Neurosciences, Inc

Minerva Neurosciences Reports Fiscal 2020 Fourth Quarter and Year End Financial Results and Business Updates

Phase 3 open-label extension completed on schedule in patients with negative symptoms of schizophrenia and data will be available in H1 2021 Minerva’s royalty interest in seltorexant acquired by...
March 01, 2021 08:30 ET | Source: Minerva Neurosciences, Inc

Minerva Neurosciences to Report Fiscal 2020 Fourth Quarter and Year End Financial Results and Business Updates on March 8, 2021

WALTHAM, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
January 19, 2021 08:00 ET | Source: Minerva Neurosciences, Inc

Minerva Neurosciences and Royalty Pharma Announce Sale of Seltorexant Royalty for up to $155 Million

WALTHAM, Mass. and NEW YORK, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV) and Royalty Pharma plc (Nasdaq: RPRX) today announced that Royalty Pharma will acquire...
December 01, 2020 08:00 ET | Source: Minerva Neurosciences, Inc

Minerva Neurosciences Announces Outcome of Type C Meeting with FDA and Next Steps in the Development of Roluperidone

WALTHAM, Mass., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
November 09, 2020 08:30 ET | Source: Minerva Neurosciences, Inc

Minerva Neurosciences to Present at Jefferies Virtual London Healthcare Conference

WALTHAM, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat...
November 02, 2020 07:30 ET | Source: Minerva Neurosciences, Inc

Minerva Neurosciences Reports Third Quarter 2020 Financial Results And Business Updates

WALTHAM, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
October 26, 2020 08:30 ET | Source: Minerva Neurosciences, Inc

Minerva Neurosciences to Report Third Quarter 2020 Financial Results and Business Updates on November 2, 2020

WALTHAM, Mass., Oct. 26, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...